REMARKS

Reconsideration of the application is requested in view of the amendments to the specification and claims and the remarks presented herein.

The claims in the application are claims 1 to 4 and 6 to 11, all other claims having been cancelled. Applicants have submitted a proper Abstract on a separate sheet of paper and the objections noted by the Examiner have been corrected.

Claims 1 to 6, 8, 11 and 12 were rejected under 35 USC 112, first paragraph as lacking support for "aralkyl" in the definition of R₂ in claim 1 and claim 8 for "pharmaceutical compound". Claim 11 was rejected as not supporting the various conditions recited therein.

Applicants traverse these grounds of rejection since the amended claims comply with 35 USC 112, first paragraph. Claim 1 has been amended to delete "aralkyl" from the definition of R₂ and claim 8 has been amended to recite "pharmaceutical carrier" which is illustrated in lines 15 to 23 of page 17. Claim 11 has been limited to the treatment of pain and claim 12 which was not rejected has been cancelled. Therefore, withdrawal of this ground of rejection is requested.

Claims 1 to 6, 11 and 12 were rejected under 35 USC 112, second paragraph as being indefinite. The Examiner pointed out that R₃ was not defined in claim 1 and

objected to certain other definitions of claim 1. Claims 4 to 6 were rejected from

inaccurate definition.

Applicants respectfully traverse this ground of rejection since the amended claims

comply with 35 USC 112. Claim 1 has been amended to provide the definition of R₃ and

R₄ has been corrected as noted by the Examiner. The typo in R₁₁ of claim 1 has been

changed to -the- and the duplication of "has" is corrected. Claim 4 has corrected the typo

of "to" and claim 5 has been amended to be properly dependent on claim 1. Claim 6 has

been amended as suggested by the Examiner. Claim 1 has been amended to define Y as

aryl without Markush terminology. Therefore, the amended claims are proper and

withdrawal of this ground of rejection is requested.

In view of the amendments to the claims and the above remarks, it is believed that

the claims point out Applicants' patentable contribution. Therefore, favorable

reconsideration of the application is requested.

Respectfully submitted,

Hedman and Costigan

Charles A. Muserlian #19,68

Attorney for Applicants

Tel. 212 302 8989

CAM:mlp Enclosures

11